Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | KAT8 | Q9H7Z6 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25525583 | 1.00 | BTK (0.62) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL3900940 | 0.91 | BTK (0.54) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL3899249 | 0.91 | BTK (0.54) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL5549963 | 0.91 | BTK (0.54) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL5524221 | 0.91 | BTK (0.54) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL23236574 | 0.90 | BTK (0.61) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL24449601 | 0.87 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL25319683 | 0.87 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL20689413 | 0.87 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL21027650 | 0.87 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981882-B1 | Compound for inhibiting IDO, a manufacturing method and a use thereof | SHANGHAI JOYU PHARMATECH LTD. (CN) | 2021-04-20 | — | — | US | disclosed |
| US-20210107882-A1 | COMPOUND FOR INHIBITING IDO, A MANUFACTURING METHOD AND A USE THEREOF | SHANGHAI JOYU PHARMATECH LTD. (CN) | 2021-04-15 | — | — | US | disclosed |
| EP-3036231-B1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | JUBILANT BIOSYS LTD (IN) | 2020-02-26 | — | — | EP | disclosed |
| US-10273224-B2 | Substituted pyrimidine compounds, compositions and medicinal applications thereof | JUBILANT BIOSYS LIMITED (IN) | 2019-04-30 | — | — | US | disclosed |
| US-20160207905-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2016-07-21 | — | — | US | disclosed |
| WO-2015025197-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | JUBILANT BIOSYS LIMITED (IN) | 2015-02-26 | — | — | WO | disclosed |
| EP-1250340-B1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-1250340-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001046199-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107882-A1 | COMPOUND FOR INHIBITING IDO, A MANUFACTURING METHOD AND A USE THEREOF | IDO1, IDO2, KYNU | BTK 2545/4885KMT2A 879/4885L3MBTL1 672/4885 |
| US-10981882-B1 | Compound for inhibiting IDO, a manufacturing method and a use thereof | IDO1, IDO2, KYNU | BTK 2698/4885KMT2A 626/4885L3MBTL1 234/4885 |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | ABCC1, ABCB11, ABCB1 | BTK 4850/4885KMT2A 4688/4885L3MBTL1 1816/4885 |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ABCC1, ABCB11, ABCB1 | BTK 4847/4885KMT2A 4622/4885L3MBTL1 1466/4885 |
| US-20160207905-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | TYMP, EGFR, TK1 | BTK 362/4885KMT2A 4738/4885L3MBTL1 4743/4885 |
| US-10273224-B2 | Substituted pyrimidine compounds, compositions and medicinal applications thereof | TYMP, EGFR, TK1 | BTK 362/4885KMT2A 4738/4885L3MBTL1 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.